News archive
Showing 742 results
June 2017
-
Media Release
Novartis pivotal CTL019 6-month follow-up data show durable remission rates in children, young adults with r/r B-cell ALL
- 83% of patients achieved complete remission (CR) or CR with incomplete blood count recovery within 3 months of treatment with CTL019; consistent with interim ELIANA data- Data evaluating 63… -
Media Release
Novartis pivotal CTL019 6-month follow-up data show durable remission rates in children, young adults with r/r B-cell ALL
-
Media Release
Novartis interim results from global, pivotal CTL019 trial show durable complete responses in adults with r/r DLBCL
-- At interim analysis, three-month overall response rate (ORR) was 45%, with 37% complete response (CR); all patients in CR at three months remained in CR at data cutoff-- Best ORR was 59%, with 43… -
Media Release
Novartis interim results from global, pivotal CTL019 trial show durable complete responses in adults with r/r DLBCL
May 2017
-
Media Release
Novartis receives FDA approval for first-of-its-kind Kisqali® Femara® Co-Pack for initial treatment of HR+/HER2- advanced or metastatic breast cancer
Physicians now have the option of prescribing Kisqali and Femara together in one convenient co-pack Co-Pack allows patients ability to obtain Kisqali and Femara with a single co-pay Approval comes… -
Media Release
Novartis receives FDA approval for first-of-its-kind Kisqali® Femara® Co-Pack for initial treatment of HR+/HER2- advanced or metastatic breast cancer
April 2017
-
Media Release
Novartis expands global collaboration with Amgen to commercialize first-in-class AMG 334 (erenumab) program in migraine prevention in the U.S. and Canada
Novartis and Amgen to co-commercialize AMG 334 (erenumab) in the U.S.; Novartis to gain exclusive rights in CanadaNovartis retains commercial rights in rest of world; Amgen retains commercial rights… -
Media Release
Novartis expands global collaboration with Amgen to commercialize first-in-class AMG 334 (erenumab) program in migraine prevention in the U.S. and Canada
-
Media Release
Novartis CAR-T cell therapy CTL019 receives FDA Breakthrough Therapy designation for treatment of adult patients with r/r DLBCL
-- Designation prioritizes investigational CTL019 (tisagenlecleucel) as a potential treatment for adult patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL)-- R/r DLBCL, an… -
Media Release
Novartis CAR-T cell therapy CTL019 receives FDA Breakthrough Therapy designation for treatment of adult patients with r/r DLBCL
March 2017
-
Media Release
Novartis announces first CAR-T cell therapy BLA for pediatric and young adult patients with r/r B-cell ALL granted FDA Priority Review
Priority review for investigational CTL019 (tisagenlecleucel-T), a novel therapy that is manufactured for each individual patient using their own T cellsNovartis made an early commitment to the… -
Media Release
Novartis announces first CAR-T cell therapy BLA for pediatric and young adult patients with r/r B-cell ALL granted FDA Priority Review